Risedon Plus35 mg+500 mg

Risedon Plus is a combination pack of a bisphosphonate (risedronate) tablet together with a calcium supplement, used in the management of metabolic bone disease. Indications are classified below by strength of evidence.

Established / approved uses (risedronate component)

• Treatment and prevention of osteoporosis in postmenopausal women, to reduce the risk of vertebral and hip fractures
• Treatment to increase bone mass in men with osteoporosis
• Treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are expected to receive long-term corticosteroid therapy
• Treatment of Paget's disease of bone in men and women

Role of the calcium component (adjunct use)

• The calcium tablets supplied as part of Risedon Plus are an adjunct, taken on the days risedronate is not taken, to help meet daily calcium requirements and support bone mineralization during bisphosphonate therapy; calcium alone does not treat osteoporosis or Paget's disease and must be used together with the risedronate component as directed.

Risedon Plus is not indicated for use in children, and is not a first-line option in premenopausal women outside clearly established, physician-directed situations.

Risedronate Sodium + Calcium is supplied as a combination regimen: risedronate sodium tablets (strength depends on the prescribed regimen, e.g. 5 mg once daily, 35 mg once weekly, 75 mg on two consecutive days once monthly, or 150 mg once monthly, each equivalent to the labeled amount of risedronic acid) supplied together with calcium tablets (commonly calcium carbonate providing elemental calcium, e.g. 500 mg) to be taken on the non-risedronate days of the cycle, as per the specific product pack instructions.

Risedon Plus is a combination product that pairs a nitrogen-containing bisphosphonate (risedronate sodium) with a calcium supplement, packaged so that patients take risedronate on specific scheduled days and calcium on the remaining days of the cycle.

Risedronate binds strongly to bone mineral and inhibits osteoclast-mediated bone resorption, slowing bone turnover and increasing bone mineral density over time. The calcium component is included to help ensure adequate calcium intake, which supports bone mineralization and reduces the risk of hypocalcemia that can occur with bisphosphonate therapy, particularly in patients with inadequate dietary calcium.

Risedon Plus is used long-term under medical supervision, with periodic reassessment of bone mineral density and continued need for therapy.

Bisphosphonate (anti-resorptive bone agent) combined with a calcium supplement — Risedon Plus

Risedronate Sodium + Calcium combines two agents with complementary actions on bone:

• Risedronate sodium is a pyridinyl bisphosphonate that binds avidly to hydroxyapatite in bone mineral, concentrating at sites of active bone remodeling. It is selectively taken up by osteoclasts and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal function and reducing bone resorption. Over time this reduces bone turnover, increases bone mineral density, and lowers fracture risk.
• Calcium is an essential mineral required for bone mineralization. Supplementing calcium alongside risedronate helps maintain normal serum calcium levels and supports the mineralization of newly formed bone during anti-resorptive therapy.

Oral bioavailability of risedronate is low (roughly 0.6%) and is further reduced when taken with food, calcium, or other divalent cations, which is why the risedronate and calcium components of Risedronate Sodium + Calcium are taken at separate times.

Correct administration is essential for both efficacy and safety of the risedronate component of Risedon Plus:

• Take the risedronate tablet first thing in the morning, at least 30 minutes before the first food, beverage (other than plain water), or other oral medication of the day.
• Swallow the tablet whole with a full glass (at least 120 mL) of plain water only; do not use mineral water, coffee, tea, juice, or milk.
• Remain fully upright (sitting or standing) for at least 30 minutes after taking the tablet, and until after the first food of the day, to reduce the risk of esophageal irritation.
• Do not lie down or go back to bed after taking the tablet.
• Do not chew or suck the tablet.
• Take the calcium tablet(s) on the scheduled non-risedronate days, with or without food, as directed on the pack; do not take calcium within the same 30-minute window as the risedronate dose.
• If a dose is missed, follow the product's specific missed-dose instructions or consult a physician/pharmacist rather than doubling up.

Clinically significant interactions relevant to Risedon Plus:

• Calcium, antacids, and mineral supplements (aluminum, magnesium, iron): significantly reduce absorption of the risedronate component if taken close together; this is why the calcium tablets in Risedon Plus are scheduled on separate days/times from the risedronate tablet, and other calcium-containing products or antacids must be avoided within 30 minutes of the risedronate dose.
• Food and beverages other than plain water: markedly reduce risedronate absorption; the risedronate tablet must be taken on an empty stomach as described in Administration.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin: concurrent use may add to the risk of upper gastrointestinal irritation; use with caution, particularly with high-dose or chronic NSAID use.
• Other oral medications in general: separating them from the risedronate dose by at least 30 minutes minimizes absorption interference; discuss timing with a pharmacist for any additional daily medication.

Reported side effects of Risedon Plus:

Common

• Abdominal pain, dyspepsia, nausea, diarrhea, or constipation
• Musculoskeletal pain (back pain, arthralgia, myalgia)
• Headache
• Mild, transient reduction in serum calcium

Less common / serious

• Esophageal irritation, esophagitis, or esophageal ulceration (see Precautions and Warnings)
• Osteonecrosis of the jaw (rare; see Precautions and Warnings)
• Atypical femur fractures with long-term use (rare; see Precautions and Warnings)
• Ocular inflammation such as uveitis or scleritis (rare)
• Hypersensitivity reactions, including skin rash

Patients should seek prompt medical attention for chest pain, worsening heartburn, difficulty or pain on swallowing, new thigh or groin pain, or jaw pain/swelling.

Pregnancy: Risedon Plus should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Bisphosphonates are retained in bone for a prolonged period and may theoretically affect fetal skeletal development if used before or during pregnancy; the risedronate component of Risedon Plus is generally avoided in women who are or may become pregnant unless there is a compelling medical reason, and a physician should be consulted before use.

Lactation: It is not known whether risedronate passes into human milk. Because of the potential for effects on infant bone development, Risedon Plus should be used during breastfeeding only if clearly needed and under medical supervision; the calcium component alone is generally considered compatible with breastfeeding at recommended doses.

Important precautions when using Risedon Plus:

• Esophageal and upper GI irritation: the risedronate component can cause esophagitis, esophageal ulcers, or erosions. Strict adherence to the administration instructions (full glass of plain water, remaining upright, empty stomach) reduces this risk. Discontinue and seek medical advice if symptoms of esophageal irritation (dysphagia, new or worsening heartburn, retrosternal pain) develop.
• Osteonecrosis of the jaw (ONJ): a rare but serious risk, more likely with invasive dental procedures during treatment, poor oral hygiene, or pre-existing dental disease. Patients should have a dental examination before starting long-term bisphosphonate therapy and inform their dentist that they are taking Risedon Plus.
• Atypical femur fractures: rare, low-trauma femoral shaft fractures have been reported with long-term bisphosphonate use; new thigh, hip, or groin pain should be evaluated promptly.
• Hypocalcemia: ensure adequate calcium and vitamin D intake before and during treatment; correct pre-existing hypocalcemia before starting.
• Renal impairment: use with caution in mild-to-moderate renal impairment and avoid in severe renal impairment (see Contraindications and Use in Special Populations).
• Musculoskeletal pain: severe and occasionally incapacitating bone, joint, or muscle pain has been reported; discuss with a physician if this occurs.

Overdose with the risedronate component of Risedon Plus may cause hypocalcemia, hypophosphatemia, and upper gastrointestinal irritation (esophagitis, gastritis, ulceration). There is no specific antidote.

If overdose is suspected, seek immediate medical attention or contact a poison control center. Milk or calcium-containing antacids may be given to bind risedronate and reduce absorption while awaiting medical care, but the patient should remain upright and not be made to vomit, because of the risk of esophageal irritation. Do not attempt specific home treatment beyond this without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: no dose adjustment of Risedon Plus is generally needed in mild-to-moderate renal impairment; use is not recommended in severe renal impairment (see Contraindications).

Hepatic impairment: no specific dose adjustment has been established; limited data are available, so use with caution.

Elderly: no dose adjustment is required based on age alone; elderly patients should be monitored for renal function and adherence to administration instructions.

Children: safety and efficacy of Risedon Plus have not been established in children; see Pediatric Uses.

For osteoporosis, Risedon Plus (risedronate component) is typically used for 3 to 5 years, after which the physician reassesses fracture risk and bone mineral density to decide whether to continue, extend, or pause therapy (a "drug holiday" is sometimes considered). For Paget's disease of bone, the risedronate component is usually given as a defined 2-month course, which may be repeated if the disease relapses, based on physician assessment. The calcium component is generally continued for as long as the risedronate component is being used, per the product regimen.

Bisphosphonates; Calcium supplements (mineral/electrolyte replacement agents)

The risedronate component of Risedronate Sodium + Calcium binds to bone mineral and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, disrupting the intracellular signaling and cytoskeletal organization osteoclasts need to resorb bone. This reduces bone turnover and increases bone mineral density. The calcium component supplies elemental calcium to support mineralization of bone matrix and helps offset the risk of hypocalcemia associated with reduced bone turnover during bisphosphonate therapy.

C

The safety and efficacy of the risedronate component of Risedon Plus have not been established in pediatric patients, and it is not approved for use in children. Growing bone has different remodeling dynamics than adult bone, and bisphosphonates are generally reserved for select pediatric bone conditions only under specialist supervision and outside the scope of this combination product. Risedon Plus should not be given to children unless specifically directed by a pediatric specialist.